JPMorgan Chase & Co. Lowers Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target to $10.00

Recursion Pharmaceuticals (NASDAQ:RXRX – Free Report) had its target price decreased by JPMorgan Chase & Co. from $11.00 to $10.00 in a research note issued to investors on Monday, Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the stock. Separately, Needham & Company LLC decreased their target price on Recursion Pharmaceuticals […]

Leave a Reply

Your email address will not be published.

Previous post HC Wainwright Cuts MacroGenics (NASDAQ:MGNX) Price Target to $12.00
Next post IQVIA (NYSE:IQV) Price Target Lowered to $239.00 at JPMorgan Chase & Co.